A quick finger prick and a few drops of blood on a card that can be sent in regular mail—This approach could soon make Alzheimer's testing much more accessible worldwide. A European study led by ...
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
GlobalData on MSN15h
How decentralisation can fill the gaps in Alzheimer’s researchAlzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
Worldcrunch on MSN3d
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’sThe first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
4d
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
The EMA has changed its mind about an earlier decision that the risks of Leqembi (lecanemab) outweigh the benefits and is now recommending the Alzheimer’s disease drug is approved for a subgroup of ...
Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback